XDH and metabolic dysfunction-associated steatohepatitis: Compared with allopurinol, febuxostat decreased hepatic uric acid levels and xanthine oxidase activity in the non-alcoholic steatohepatitis (NASH) mouse model, which was accompanied by more effective prevention of certain features of NASH, including insulin resistance, lipid peroxidation, and liver inflammation, indicating greater efficiency in preventing liver metastasis 86.